|
|
Middle East Journal of Cancer، جلد ۹، شماره ۳، صفحات ۱۹۵-۰
|
|
|
| عنوان فارسی |
|
|
| چکیده فارسی مقاله |
|
|
| کلیدواژه‌های فارسی مقاله |
|
|
| عنوان انگلیسی |
Metastatic Urothelial Tumor Progression Following First Line Chemotherapy: Prognostic Factors and Importance of Second Line Chemotherapy |
|
| چکیده انگلیسی مقاله |
Background: Limited data exists to support the benefit from second-line chemotherapy in patients with metastatic urothelial carcinoma. Factors that predict survival following progression after first-line platinum-based regimens in patients treated outside clinical trials are not clear. This study intends to evaluate different prognostic factors and the impact of second-line chemotherapy on survival. Methods: We retrospectively reviewed patients with metastatic urothelial carcinoma who experienced disease progression following first-line platinum-based regimens for metastases. These patients received treatment and follow up visits at a single institution. The effect of demographic, disease characteristics, and second-line therapy on overall survival was examined through univariate and multivariate cox-regression analyses. Results: There were 64 patients included. A total of 27 (42%) patients did not receive second-line chemotherapy because of poor Eastern Cooperative Oncology Group performance status, 20 (31%) received combination chemotherapy (platinum-based in 17), and 17 (27%) received a single agent chemotherapy. The median overall survival from the date of documented progression after first-line therapy was 5.0 months. In multivariate analysis, a correlation existed between poor overall survival and performance status of ≥1 (HR: 5.74, 95% CI: 1.4- 45.57, P =0.036), no second-line chemotherapy (HR: 2.72, 95% CI: 1.39-5.31, P =0.003), and ≥2 metastatic sites (HR: 5.19, 95% CI: 1.74-15.44, P < 0.001). Conclusion: A significant proportion of patients with metastatic urothelial carcinoma were not eligible for second-line chemotherapy because of poor performance status. Use of second-line chemotherapy, Eastern Cooperative Oncology Group performance status, and number of metastatic sites were important determinants of survival. |
|
| کلیدواژه‌های انگلیسی مقاله |
|
|
| نویسندگان مقاله |
| Mohammad S. Ma’koseh
Department of Medical Oncology, King Hussein Cancer Center, Amman, Jordan
| Rami A. Al-wardat
Department of Medical Oncology, King Hussein Cancer Center, Amman, Jordan
| Murad Y. Salam
Department of Medical Oncology, King Hussein Cancer Center, Amman, Jordan
| Samer H. Salah
|
|
| نشانی اینترنتی |
http://mejc.sums.ac.ir/index.php/mejc/article/view/668 |
| فایل مقاله |
اشکال در دسترسی به فایل - ./files/site1/rds_journals/181/article-181-677062.pdf |
| کد مقاله (doi) |
|
| زبان مقاله منتشر شده |
en |
| موضوعات مقاله منتشر شده |
|
| نوع مقاله منتشر شده |
Original Article |
|
|
|
برگشت به:
صفحه اول پایگاه |
نسخه مرتبط |
نشریه مرتبط |
فهرست نشریات
|